Two Seas Capital LP Takes Position in Sotera Health Company $SHC

Two Seas Capital LP acquired a new stake in shares of Sotera Health Company (NASDAQ:SHC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 5,836,053 shares of the company’s stock, valued at approximately $103,590,000. Sotera Health comprises 2.1% of Two Seas Capital LP’s investment portfolio, making the stock its 11th largest holding. Two Seas Capital LP owned approximately 2.05% of Sotera Health at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Empowered Funds LLC increased its position in Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after buying an additional 2,845 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after acquiring an additional 43,471 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Sotera Health by 125.5% during the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares during the last quarter. Creative Planning grew its stake in shares of Sotera Health by 15.3% during the second quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after acquiring an additional 2,673 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Sotera Health by 4.2% during the second quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after acquiring an additional 12,758 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on SHC shares. JPMorgan Chase & Co. increased their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a research report on Friday, June 5th. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings raised shares of Sotera Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Barclays upped their price target on shares of Sotera Health from $19.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, UBS Group set a $19.00 price target on shares of Sotera Health in a report on Wednesday, June 24th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Sotera Health has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Insider Buying and Selling

In other news, insider Michael P. Rutz sold 150,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total value of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares of the company’s stock, valued at $6,297,816.36. This represents a 30.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the completion of the sale, the chairman owned 3,969,393 shares in the company, valued at $73,433,770.50. The trade was a 17.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,294,515 shares of company stock valued at $23,999,528 over the last three months. 15.36% of the stock is currently owned by insiders.

Sotera Health Stock Up 1.8%

Sotera Health stock opened at $19.57 on Friday. The business’s 50-day simple moving average is $17.77 and its two-hundred day simple moving average is $16.36. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. The company has a market cap of $5.58 billion, a PE ratio of 34.33 and a beta of 1.77. Sotera Health Company has a fifty-two week low of $13.09 and a fifty-two week high of $19.85.

Sotera Health (NASDAQ:SHC) last released its earnings results on Thursday, August 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The firm had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The company’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities analysts anticipate that Sotera Health Company will post 0.86 EPS for the current year.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.